Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled time : 13:30 save search
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
PHGE | $0.3274 -5.51% 3.82% 130K
|
Health Technology
|
| O: 9.27%
H: 6.06%
C: 6.06%
bx004 treatment fibrosis for study
FDA Rejects Abeona’s Gene Therapy, Approves ImmunityBio’s Bladder Cancer Treatment
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: 0.13%
H: 1.89%
C: 1.3%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 0.56%
H: 0.41%
C: -0.07%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
fda bladder cancer treatment
Soil Treatment Market size is set to grow by USD 16.46 billion from 2023-2027, Need to meet rising demand for crops boost the market, Technavio
Published: 2024-04-10 (Crawled : 13:30) - prnewswire.com
CODYY | $15.08 -0.13% 1.6M
|
Manufacturing
|
| O: -3.01%
H: 1.44%
C: 0.84%
treatment for set market
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
Published: 2024-04-04 (Crawled : 13:30) - globenewswire.com
FBLG | $11.55 4.05% 3.9% 69K
|
|
| O: -0.85%
H: 2.75%
C: 2.75%
treatment care mouse advanced diabetes usa
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
Published: 2024-03-28 (Crawled : 13:30) - globenewswire.com
FBLG | $11.55 4.05% 3.9% 69K
|
|
| O: -1.87%
H: 0.0%
C: -6.24%
patent lupus treatment application technology potential
FDA Approves New Treatments for Two Rare Diseases
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: 0.84%
H: 1.48%
C: 1.29%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
fda rare
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment
Published: 2024-03-19 (Crawled : 13:30) - prnewswire.com
FBLG | $11.55 4.05% 3.9% 69K
|
|
| O: 0.11%
H: 38.0%
C: 21.22%
treatment diabetes
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-03-06 (Crawled : 13:30) - prnewswire.com
GNPX | $2.31 6.77% 20K
|
Health Technology
|
| O: 24.27%
H: 5.66%
C: -14.45%
reqorsa lung positive treatment system preclinical meeting therapy
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-03-04 (Crawled : 13:30) - prnewswire.com
NRXP 5 d | $3.11 1.97% 1.93% 96K
|
Manufacturing
|
| O: -1.85%
H: 27.88%
C: 20.93%
nrx-101 depression treatment pharmaceuticals trial
ALS Treatment Landscape ‘Primed’ with Over 100 Candidates: GlobalData
Published: 2024-03-04 (Crawled : 13:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
als treatment 100
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
ICPT | $19.0 -0.05% 4M
|
Health Technology
| Email alert
Add to watchlist
ocaliva fda drug treatment application
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
SWTX | $43.37 -1.43% -1.45% 470K
|
Health Technology
|
| O: 2.2%
H: 1.21%
C: -0.85%
tumors authorization treatment application therapeutics
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
SPRC | $1.215 -1.22% -1.23% 76K
|
Manufacturing
|
| O: -1.07%
H: 8.11%
C: 3.24%
treatment enabling trial
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
Published: 2024-02-12 (Crawled : 13:30) - globenewswire.com
ABVC | $1.475 9.26% 8.47% 6.3M
|
Wholesale Trade
|
| O: -0.76%
H: 3.05%
C: 2.29%
treatment biopharma
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
Published: 2024-02-12 (Crawled : 13:30) - biospace.com/
TGTX | $13.99 -1.83% -1.86% 2.7M
|
Health Technology
|
| O: 1.15%
H: 1.88%
C: 1.81%
DTIL | $9.81 -4.11% -4.28% 34K
|
Health Technology
|
| O: 1.56%
H: 3.51%
C: -3.82%
precision million payment treatment therapeutics
CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
BHC | $8.56 0.35% 0.0% 2M
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: -1.33%
treatment gel acne
Alexandria Real Estate Equities, Inc. Announces Tax Treatment of Year 2023 Distributions
Published: 2024-01-26 (Crawled : 13:30) - prnewswire.com
ARE | News 4 | $119.65 0.13% 2.16% 880K
|
Finance
|
| O: 0.32%
H: 0.61%
C: 0.44%
year treatment
Apollo Commercial Real Estate Finance, Inc. Announces 2023 Dividend Income Tax Treatment
Published: 2024-01-22 (Crawled : 13:30) - globenewswire.com
ARI | $10.84 -1.54% 0.0% 590K
|
Finance
|
| O: 0.51%
H: 0.89%
C: -0.59%
treatment commercial
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
Published: 2024-01-09 (Crawled : 13:30) - globenewswire.com
SLS | $1.54 -5.52% -5.84% 1.3M
|
Health Technology
|
| O: 3.82%
H: 3.33%
C: 0.28%
sls009 fda life treatment designation sciences leukemia study
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TGTX | $13.99 -1.83% -1.86% 2.7M
|
Health Technology
|
| O: -8.22%
H: 9.05%
C: 7.47%
DTIL | $9.81 -4.11% -4.28% 34K
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
license cell treatment deal therapeutics therapy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.